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1. Introduction 
Insomnia is a symptom, not a stand-alone disease. By definition, insomnia is "difficulty 
initiating or maintaining sleep, or both" or the perception of poor quality sleep (APA, 1994). 
As an adverse effect of medicines, it has been documented for several drugs. This chapter 
describes some drugs whose safety profile includes insomnia. In doing so, it discusses the 
mechanisms through which drug-induced insomnia occurs, the risk factors associated with 
its occurrence, and ends with some guidance on strategies to prevent and manage drug-
induced insomnia.  
2. How drugs induce insomnia 
There are several mechanisms involved in the induction of insomnia by drugs. Some drugs 
affects sleep negatively when being used, while others affect sleep and lead to insomnia 
when they are withdrawn. Drugs belonging to the first category include anticonvulsants, 
some antidepressants, steroids and central nervous stimulant drugs such amphetamine and 
caffeine. With regard to caffeine, the mechanism by which caffeine is able to promote 
wakefulness and insomnia has not been fully elucidated (Lieberman, 1992). However, it 
seems that, at the levels reached during normal consumption, caffeine exerts its action 
through antagonism of central adenosine receptors; thereby, it reduces physiologic 
sleepiness and enhances vigilance (Benington et al., 1993; Walsh et al., 1990; Rosenthal et al., 
1991; Bonnet and Arand, 1994; Lorist et al., 1994). In contrast to caffeine, methamphetamine 
and methylphenidate produce wakefulness by increasing dopaminergic and noradrenergic 
neurotransmission (Gillman and Goodman, 1985). With regard to withdrawal, it may occur 
in 40% to 100% of patients treated chronically with benzodiazepines, and can persist for 
days or weeks following discontinuation. Withdrawal symptoms include dizziness, 
confusion, and depression (Lader et al., 2009).  
Another feature of discontinuation of drugs is rebound insomnia, which is an increase in 
insomnia symptoms beyond their baseline level. Rebound is thought to be associated 
primarily with short-acting benzodiazepines. Patients who demonstrate rebound insomnia 
tend to have worse baseline sleep and higher medication doses than patients without 
rebound (Merlotti et al., 1991; Roehrs et al., 1986; Hajak et al., 1998; Griffiths and Weerts, 
1997). While insomnia can also result from chronic use of hypnotics such as 
benzodiazepines and other sedatives, the following classes of drugs can cause insomnia 
when withdrawn: central nervous depressants such as alcohol, certain antidepressants, and 
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barbiturates, opioids both legal and illicit such as cocaine, heroin, marijuana; as well as 
monoamine oxidase inhibitors and phencyclidine.  
Moreover, it is known that adrenal dysfunction can cause catecholamine secretion that may 
lead to sympathetic activation and insomnia. Similarly, excessive glucocorticoid levels also 
cause insomnia (Attarian, 2004). Furthermore, an indirect effect through neurologic and 
psychiatric effects such as headaches, irritability, anxiety and agitation may also lead to 
insomnia. This is the case for commonly prescribed hypnotics that cause irritability and 
many psychoactive drugs that induce abnormal movements during sleep (Zammit et al., 
1999; Breslau et al., 1996). Drugs which suppress rapid eye movement (REM), commonly 
result in REM rebound nightmares on withdrawal, as in the case of opioid analgesics. While 
such drugs are being taken, the relative lack of REM sleep may lead to underestimation of 
the severity of sleep apnea. Drugs which suppress slow-wave sleep (SWS) commonly leave 
the patient unrested, as seen with corticosteroids.  
Parasomnias, defined as unusual behaviours during sleep such as sleepwalking, sleep-
talking, teeth grinding, bedwetting, sleep starts, sleep terrors, and confusion awakenings are 
sleep disturbances associated and leading to drug-induced insomnia. Sleepwalking may 
occur in over 15% of healthy children and 3% of adults, typically take place during short 
wave sleep. Several medications which increase this stage of sleep may induce sleep-
walking: lithium, thioridazine, and amitriptyline. Drugs that suppress REM sleep increase 
the likelihood of some parasomnias: tricyclic antidepressants, for example, and triazolam. 
Nightmares, reported at least occasionally by 40-50% of adults, are known to be associated 
with REM sleep (Novak and Shapiro, 1997).  
Drugs which predispose to nightmares include beta-blockers, especially those that more 
easily penetrate into the brain, like propranolol. Stimulant drugs which disrupt night-time 
sleep include theophylline and sympathomimetic bronchodilators such as ephedrine. Drugs 
which may worsen sleep apnea include alcohol, opioid analgesics, and anaesthetic drugs. 
Among the cardiovascular drugs, some antihypertensive drugs are particularly important in 
their effects on sleep, generally a decrease in the duration of REM sleep, but it is unclear 
how significant these effects are for patients. REM sleep is decreased by blockers of beta-
adrenoreceptors like pindolol, stimulants of alpha adrenoreceptors like clonidine and 
guanfacine, serotonin stimulators like ritanserin and ketanserin, and methyldopa. Only 
reserpine increases REM sleep. Beta-blockers like propranolol in particular increase 
wakefulness by causing insomnia and nightmares, and by suppressing REM sleep. 
However, the frequency of these effects may be low, especially with types of beta-blockers 
that do not readily penetrate to the brain, like atenolol (Novak and Shapiro, 1997; Roehrs et 
al., 2000; Roth and Roehrs, 2003).  
Other drugs produce insomnia by interfering with melatonin. Melatonin has the ability to 
influence the timing of the circadian sleep-wake cycle (Sack et al., 2000), has sedative effects 
possibly via direct inhibition of the suprachiasmatic nucleus via a feedback loop 
(Dubocovitch, 1995). It is suggested that melatonin promotes sleep in humans, presumably 
by inhibiting circadian wakefulness mechanisms and affecting the activity of brain networks 
compatible with sleep induction (Cajochen et al., 2003; Wyatt et al., 200; Liu et al., 1997; 
Shocaht et al., 1997; Gorfine et al., 2006). However, numerous studies have shown decreased 
melatonin levels in the elderly relative to subjects aged less than 30 years (Sharma et al, 
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1989; Zhou et al., 2003) because of the decline in the number of pinealocytes, and/or 
neuronal degeneration and resultant circadian desynchrony (Kripke et al., 1998). Yet, 
melatonin deficiency many be induced by a variety of medications commonly used by the 
elderly, including beta-blockers and non-steroidal anti-inflammatory drugs (Gorfine et al., 
2006; Liu et al., 1997).  
 
Box 1. Mechanisms involved in drug induction of insomnia 
3. Risk factors of drug-induced insomnia 
From the mechanisms of action described above, it is appears that several factors would 
contribute to the occurrence of insomnia as a result of using a particular drug or 
withdrawing it. Reports of sleep disturbances associated with therapeutic drugs appeared in 
the 1970s and 1980s. Nightmares were observed with the initiation or withdrawal of tricyclic 
Examples of classes of drugs inducing insomnia and their mechanisms of action 
Through melatonin 
 Beta-blockers 
 Non-steroidal anti-inflammatory drugs 
Through interfering with REM 
 Beta-blockers 
 Tricyclic antidepressants: eg. 
 Stimulant drugs : eg. Theophylline 
 Serotonin stimulators: eg. ritanserin 
Through interfering with slow-wave sleep 
 Corticosteroids 
Through increasing dopaminergic and noradrenergic neurotransmission 
 methamphetamine  
 methylphenidate 
Through withdrawal 
 Benzodiazepines 
 Barbiturates  
 Opioids such as cocaine, heroin, marijuana 
Through direct action by antagonism of central adenosine receptors 
 Caffeine 
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antidepressants and with the use of neuroleptic drugs (Strayhorn and Nash, 1978). Although 
levodopa was introduced in the 1960s, reports of levodopa-induced sleep disruptions did 
not appear until several years later (Sharf et al 1978).  
Factors related to a particular drug include the chemical structure of the drug that dictates 
its activities, its pharmacological mechanisms of action, and the dosage used in a particular 
patient (Lancel, 1999; Mendelson et al., 1983; Olsen and Tobin, 1990). As shown below some 
drugs induce insomnia only when a certain level of dosage is reached. Factors related to an 
individual patient include race, lower socioeconomic status, and unemployment as well as 
age, sex, use of medications and comorbidities.  
Several studies suggest there are ethnic and racial differences in sleep disturbances. Studies 
exploring associations between disturbed sleep and health-related quality of life (HR-QOL) 
have examined the role of comorbid conditions, gender, and race/ethnicity (Krystal, 2007; 
Baldwin et al., 2004; Katz and McHorney, 2002; Chowdhury et al., 2008). As with studies of 
sleep disturbances, the majority of HR-QOL research focused on differences between 
African American and Caucasian participants. Elderly African Americans with mild sleep 
apnea had significantly poorer physical and mental HRQOL than African Americans 
without it (Redline et al., 1997; Stepnowsky et al., 2000). African American, Hispanic, and 
other minority participants had both worse quality of sleep and poorer well-being than 
Caucasian participants (Jean-Louis et al., 2000). However, when sex, education, age, marital 
status, and healthcare coverage were controlled for, Caucasians were more likely to report 
not getting enough sleep than African Americans and Hispanics; when mood, medication 
use, socioeconomic status and perceived health were controlled for, Caucasians reported 
more restless sleep than African Americans (Kutner et al., 2004).  
With regard to age, as explained above, the extent of melatonin suppression may be more 
profound in the elderly than in younger subjects. In addition to medications, a variety of 
primary conditions, such as chronic pain, myocardial infarction, and ischemic stroke are 
strongly associated with decreased melatonin levels in the elderly as animal studies have 
shown decreased levels of the Mel1a receptor with aging (Garfinkel et al., 1995; Murphy et 
al., 1996; Van den Heuven et al., 1997; Richardson and Tate, 2000). The elderly constitutes a 
group of individuals who are known as more susceptible to actions of drugs such as 
antidepressants, antihistaminic drugs, certain antipsychotics, and amphetamines (Fick et al., 
2003). Furthermore, people who are elderly have a higher incidence of general medical 
conditions and are more likely to be taking medications that cause sleep disruption. Sleep 
studies objectively confirm the disturbed sleep of asthmatics. They are often woken with 
coughing, wheezing, and breathlessness. Similar problems apply to patients with chronic 
obstructive pulmonary disease (COPD or emphysema). Besides direct drug effects on their 
sleep, asthmatics suffer many other factors affecting sleep, such as gastroesophageal reflux, 
which can be aggravated by theophylline. Theophylline also has a central nervous system 
stimulatory effect that can disturb sleep, particularly in patients newly taking this drug. 
With regard to commonly used medications, the following medicines are reported to 
promote chronic insomnia. These include selective serotonin reuptake inhibitors, 
lamotrigine, phenytoin, atorvastatin and oral contraceptives. Other risk factors of insomnia 
include the patient’s health status, susceptibility, and co-morbidity (Balter and Uhlenhuth, 
1992; Sharpley and Cowen, 1995;Espiritu, 2008; Saddichha, 2010).  
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With regard to comorbidities, the incidence of insomnia in hypertensive Japanese patients 
under antihypertensive therapy has been reported as 0.77/100 person-years; the factors 
contributing to insomnia onset were ┙ blockers (OR, 2.38; 95% confidence interval [CI], 1.14-
4.98), ┚ blockers (OR, 1.54; 95% CI, 0.99-2.39), and calcium channel blockers (OR, 0.62; 95% CI, 
0.43-0.90) compared with angiotensin-converting enzyme inhibitors; female sex (OR, 1.76; 95% 
CI, 1.27-2.44); complication of gastric/duodenal disorders (OR, 2.35; 95% CI, 1.14-4.86) or 
musculoskeletal system/connective tissue disorders (OR, 2.43; 95% CI, 1.23-4.79); and 
concomitant antihypertensive therapy (Tanabe et al., 2011). In patients suffering from 
myasthenia gravis, the prevalence of insomnia was 39.1% (Qui et al., 2010). Lastly, sleep 
disturbance is one of the most common complaints reported in 74-96% of patients suffering 
from Parkinson’s disease. Insomnia is associated with increased morbidity and mortality 
caused by cardiovascular disease and psychiatric disorders and has other major public health 
and social consequences, such as accidents and absenteeism (Roth and Roehrs, 2003).  
 
Box 2. Risk factors for drug induced insomnia 
4. Specific classes of drugs reported to cause insomnia 
The following list is not comprehensive or exhaustive; it is purely presented for illustration 
purposes. 
1. Amino-quinolones 
Atovaquone plus proguanil, a combination that was used in the preventive and curative 
treatment of malaria has been reported to produce insomnia in 5.2% of patients (van 
Genderen et al., 2007). 
2. Anabolic steroids 
It is well known that the abuse of anabolic steroids can cause the stimulation of the nervous 
system and this may result in euphoria or and insomnia (Papazisis et al., 2007; Kanayama et 
al., 2008). 
3. Anti-ADHD 
Methylphenidate, a drug used to treat attention deficit hyperkinetic disorder (ADHD), was 
reported to produce insomnia in 19 of 62 patients who were included in an open label trial 
(Gucuyener et al., 2003). 
Risk factors associated with drug-induced insomnia 
 Age 
 Race and ethnicity 
 Sex 
 Medication use and drug interactions 
 Comorbidities 
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4. Anti-asthmatic drugs 
Insomnia was one of the common side effects in 84 patients who completed a randomized 
trial of albuterol/salbutamol (Kissel et al., 2001). Insomnia was also reported in 1.75% of the 
110 participants with COPD in a trial involving theophylline (Zhou et al., 2006).  
5. Antidepressants 
In an open-label phase of a relapse prevention study, duloxetine (60 mg QD) was shown to 
be effective in the treatment of depression; among the 533 participants, insomnia was 
reported in over 10% of patients (Hudson et al., 2007). 
6. Antiepileptic drugs 
Lamotrigine led to insomnia in 2 of 29 patients treated for refractory epilepsy (Garcia-
Escriva et al., 2004). Levetiracetam led to insomnia in 105 (7.5%) of 1422 patients observed 
during studies (Ben-Menachem et al., 2003; Mula et al., 2004). Insomnia was reported in 9% 
of patients who were treated with a median dose of 300mg per day of topiramate 
(Giannokodimos S et al., 2005) 
7. Antihistamines 
Insomnia has been reported in 30% taking loratadine plus pseudoephedrine versus 21% 
taking placebo (Berkowitz et al., 1989; Supiyaphun et al., 2002). 
8. Anti-muscarinic drugs 
In a meta-analysis of 72 original randomized trials of antimuscarinic drugs, namely, 
oxybutynin, tolterodine, fesoterodine, propiverine, solifenacin, darifenacin, and trospiu, 
adverse effects reported were, among others, insomnia and vertigo. The trials involved 
adults with overactive bladder using standard doses of medications (Paquette et al., 2011).  
9. Anti-obesity drugs 
Insomnia was one of the most common adverse effect of monoamine system drugs such as 
sibutramine, bupropion, and tesofensine (Nathan et al., 2010). 
10. Antipsychotic drugs 
Aripiprazole is known to produce fewer extrapyramidal effects, but in patients taking 15mg 
per day, insomnia in 42% of patients versus 18% in those taking the placebo (Shim et al., 
2007; Carvajal et al., 2007). 
In the 40-week extension of a clinical trial, insomnia was of the common adverse effects seen 
in over 10% of patients treated with asenapine (McIntyre et al., 2010). 
11. Antiretroviral drugs  
Efavirenz is known to produce neuropsychiatric effects including insomnia in up to 50% 
of patients (Kenedi and Goforth, 2011; Jena et al., 2009; Alavena et al., 2006). In a trial of 
single-pill fixed-dose regimen containing emtricitabine, tenofovir and efavirenz, four 
patients discontinued the trial because of insomnia (Airoldi et al., 2010). Insomnia has 
been reported in 5% to 16% patients on a regimen containing emtricitabine (Palacisos et 
al., 2008). 
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12. Anti-tuberculosis agents 
Of the 18 patients identified with neuropsychiatric problems in 18 French patients, six had 
insomnia (Fekih et al., 2011). 
13. Benzimidazoles 
Albendazole, in a clinical trial of 168 patients, led to insomnia in 2 patients that have been 
treated for 7 days due to heavy infestation (Sirivichayakul et al., 2003). 
14. Complementary and alternative medicines (CAM) 
Despite its voluntary recall of Pai You Guo in 2009, clinicians have noted its continued use 
among Brazilian-born women in Massachusetts. The majority of users (85%) reported at 
least one side effect, among them insomnia in 26% of respondents (Cohen et al., 2011). 
15. Cholinesterase inhibitors 
Donepezil and galantamine have been reported to have induced insomnia in some patients 
(Kavirajan and Schneider, 2007). 
16. Cox-2 inhibitors 
Celecoxib and rofecoxib, of the 142 reports received by the Australian Adverse Reactions 
Advisory Committee (ADRAC), 21 cases were about insomnia (ADRAC, 2003). This 
neuropsychiatric reaction seems to be a class effect.  
17. Fluoroquinolones 
Drugs of this group such as gatifloxacin, gemifloxacin, and moxifloxacin produce mild 
central nervous complications including insomnia (Sable and Murakawa, 2003; Sable and 
Murakawa, 2004). Other psychiatric effects include headaches, and agitation that occurred in 
2-4% of patients (Saravolatz and Leggett, 2003). In double-masked, randomized, 
comparative trials of sparfloxacin (a 400-mg oral loading dose followed by 200 mg/d for 10 
days) versus standard therapies (erythromycin, cefaclor, ofloxacin, clarithromycin, and 
ciprofloxacin), insomnia was reported in 4.3% of patients (Lipsky et al., 1999). 
18. Human-murine monoclonal antibodies 
Infliximab is used to treat refractory Crohn’s disease; in one patient suffering from lupus 
erythematous, insomnia was reported (Drosou et al., 2003). 
19. Lipopeptide antibiotics 
Daptomycin, a drug with bactericidal effects against Gram-positive bacteria has been 
reported to produce moderate neuropsychiatric effects such as headaches and insomnia 
(Gonzalez-Ruiz et al., 2011; FDA, 2003). 
20. Metals 
Antimony and arsenic: In observational studies, both antimony and arsenic caused insomnia 
in patients (Newlove et al., 2011; Takahashi, 2010). Insomnia was reported in 37.5% of 
people who were victims of chronic arsenic poisoning through drinking water in Mongolia 
(Guo et al., 2007).  
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21. Neuroleptics 
The long-acting depot risperidone has a half-life of 3-6 days. Its most common adverse 
events include insomnia which is reported in 22.6% of patients (Louza et al., 2011). Insomnia 
was  reported also as one of the common adverse effects of paliperidone in addition to 
extrapyramidal effects when used in patients with schizophrenia (Shim et al., 2008; Turkoz 
et al., 2011; Sliwa et al., 2011).  
22. Norephinephrine re-uptake inhibitor (NRI) 
Reboxetine-treated patients were more likely to experience constipation, difficulty urinating, 
and insomnia (Papakostas et al., 2008).  
23. Opioid receptor agonists 
Nalmefene, a drug used in order to promote abstinence in alcoholics, has been shown to 
induce insomnia in patients who received 20 micrograms per day (Anton et al., 2004). 
24. Opioid analgesics 
Insomnia has been reported as adverse event with dextromethorphan (Paul et al., 2004; Avis 
and Profile, 2005). 
25. Selective serotonin reuptake inhibitor (SRRI) 
Escitalopram, a selective serotonin reuptake inhibitor (SSRI) used in the treatment of major 
depressive disorder (MDD) and generalized anxiety disorder (GAD), has been reported to 
produce insomnia and decreased libido when used at 10 mg/day (Huska et al., 2007). In a 
large sample of 811 adult participants with depression in a part-randomised multicentre 
open-label study comparing escitalopram and nortriptyline, insomnia was reported in 36% 
of patients on escitalopram (Uher et al., 2009).  
26. Smoking deterrent 
In a review involving 120 studies (Mills et al., 2010), an increased risk of insomnia was 
associated with nicotine patch (OR 1.42, 95% CI, 1.21-1.66, P < 0.001) 
27. Steroids  
Insomnia has been reported in 27% of 103 patients treated for 8 days with more than 
20mg/day of prednisone (Silverman et al., 1985; Aronson, 2010). 
In an investigation of glucocorticoid-induced side effects in 68 Japanese patients treated for 
autoimmune diseases with prednisolone, insomnia occurred in 50% of them. It lasted on 
average 6 days, ranging from 1 to 88 days (Nakajima et al., 2009). 
In case series of children with such discrete conditions as asthma and nephrotic syndrome, 
up to 50% of those receiving oral glucocorticoids have had adverse behavioural and 
affective effects including elevated levels of depression and anxiety, as well as increases in 
insomnia (Estrada de la Riva, 1958; Bender et al., 1988; Hall et al., 2003). 
5. Strategies to manage drug-induced insomnia  
Given the mechanisms of action described above, prescribers and dispensers of drugs 
should alert and inform the patients of the possibility that the drug they will be taking may 
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lead to insomnia. For drugs that cause insomnia when withdrawn, the most common 
strategy has been to avoid abrupt withdrawal by tapering the dosing of the drug over 
several days (Lader et al., 2009).  
For drugs that cause insomnia when being used, there are three strategies, namely, 
modification of dosage, discontinuation of drug, and switching to a different drug. When 
switching to a different drug, it is important to ensure that the insomnia as an adverse effect 
is not a “class-related effect” as shown above with regard to fluoroquinolones or cox-2 
inhibitors. If so, a drug of a different class must be chosen or a drug that favourably 
enhances sleep should be considered as in case of salmeterol, a beta-adrenergic stimulator, 
that has been shown to improve quality of sleep. This medicine is recommended in 
asthmatics experiencing sleep disturbances (Lee et al., 2011; Nathan et al., 2006).  
When insomnia occurs at a certain dosage level as in the case of prednisone, dosage 
reduction should be considered. This strategy is most relevant for the elderly. Generally, 
lower doses should be used in the elderly, although dose requirements may vary from 
person to person. Typically, starting doses for the elderly should be about one third to one 
half of the usual adult doses when a drug has a low therapeutic index or when another 
condition may be exacerbated by the drug (Kamal and Gammack, 2006).  
With regard to preventing the occurrence of drug-induced insomnia, prescribers must be 
familiar with the drug and its potential adverse reactions. Drugs and initial dosage must be 
carefully selected for susceptible individuals such the elderly, those on cancer therapy, and 
children. Drugs which suppress slow-wave sleep (SWS) commonly leave the patient 
unrested; this might be counteracted by a sleeping medication that increases SWS, such as 
zopiclone. Clomipramine, a tricyclic antidepressant, may be used to suppress REM related 
nightmares. Both pharmacological and non-pharmacological treatment modalities should be 
explored in the management of drug-induce insomnia (Ellis et al., 2011; Foral et al., 2011). 
6. Concluding remarks 
Drug-induced insomnia is prevalent. It has been reported to occur to up to 50% of patients 
on specific drugs. While patients must be advised accordingly, precautions must be taken to 
avoid inducing insomnia through abrupt withdrawal of drugs, inappropriate dosing and 
irrational drug prescribing.  
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